Drug Insights

A Complete Guide to Searching Diphenhydramine on Synapse

6 February 2024
2 min read

Diphenhydramine (DPH) is an antihistamine and sedative mainly used to treat allergies, insomnia, and symptoms of the common cold. It is taken by mouth, injected into a vein, injected into a muscle, or applied to the skin. Maximal effect is typically around two hours after a dose, and effects can last for up to seven hours. It is a first generation H1-antihistamine and ethanolamine and works by blocking certain effects of histamine, which produces its antihistamine and sedative effects. Diphenhydramine is also a potent anticholinergic. Common side effects include sleepiness, poor coordination and an upset stomach. Click on the image below to begin the exploration journey of Diphenhydramine through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Oricell's IND Application for Innovative CAR-T Therapy, OriCAR-017
Latest Hotspot
3 min read
FDA Approves Oricell's IND Application for Innovative CAR-T Therapy, OriCAR-017
6 February 2024
Oricell has received the green light from the FDA for its investigational new drug (IND) application for OriCAR-017, an innovative CAR-T therapy aimed at GPRC5D.
Read →
Using Synapse for Your Tamsulosin Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Tamsulosin Research: An Easy Guide
6 February 2024
Tamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker.
Read →
Sarepta Therapeutics' SRP-5051 Shows Promise in MOMENTUM Phase 2 Trial for Duchenne Muscular Dystrophy
Latest Hotspot
3 min read
Sarepta Therapeutics' SRP-5051 Shows Promise in MOMENTUM Phase 2 Trial for Duchenne Muscular Dystrophy
6 February 2024
Sarepta Therapeutics Reveals Encouraging Results from Segment B in the MOMENTUM Phase 2 Trial for SRP-5051, Targeting Exon 51 Skip-Amenable Duchenne Muscular Dystrophy Cases.
Read →
Accessing Methocarbamol Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Methocarbamol Information on Synapse: A Step-by-Step Approach
6 February 2024
Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.